Spotlight Poster Discussion 15 – Friday, December 10, 2021: 7:00 am – 8:30 am CT
   
  Defining Molecular Markers of Endocrine Resistance in Clinic
PD15-01 Impact of ESR1 mutations on endocrine therapy (ET) plus alpelisib benefit in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated, advanced breast cancer (ABC) who progressed on or after prior cyclin-dependent kinase inhibitor (CDK4/6i) therapy in the BYLieve trial
Turner N, Rugo HS, Ciruelos EM, Ruiz-Borrego M, Drullinsky P, Lerebours F, Prat A, Bachelot T, Chia S, Balbin A, Joshi M, Roux E, Arce CH, Akdere M, Juric D. The Royal Marsden NHS Foundation Trust, London, United Kingdom University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Hospital Universitario 12 de Octubre, Madrid, Spain Hospital Virgen del Rocio de Sevilla, Seville, Spain Memorial Sloan Kettering Cancer Center, New York, NY; Institut Curie, Saint-Cloud, France Hospital Clinic of Barcelona, Barcelona, Spain Centre Léon Bérard, Lyon, France British Columbia Cancer Agency, University of British Columbia, Vancouver, BC, Canada Novartis Institutes for BioMedical Research, Boston, MA; Novartis Pharma AG, Basel, Switzerland Novartis Pharmaceuticals Corporation, East Hanover, NJ; Massachusetts General Hospital Cancer Center, Boston, MA.
PD15-02 HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer
Bergamino Sirvén MA, López-Knowles E, Morani G, Tovey H, Kilburn L, Holcombe C, Skene A, Smith I, Robertson J, Schuster G, Bliss JM, Dowsett M, Cheang MCU, POETIC investigators. The Institute of Cancer Research, London, United Kingdom Liverpool University Hospitals, Liverpool, United Kingdom Birmingham's Women and Children, Birmingham, United Kingdom Royal Marsden Hospital, London, United Kingdom The University of Nottingham, Nottingham, United Kingdom.
PD15-03 Overlapping molecular features (proliferation, immune signatures andTP53mutations) associated with palbociclib resistance inER+HER2- primary breast cancer
Schuster EF, Xiao H, Cheang M, Lopez-Knowles E, Kilburn L, Korchina V, Salvi S, Jacobs SA, Finnigan M, Wheeler DA, Puhalla S, Muzny D, Doddapaneni H, Pogue-Geile K, Liu Y, Bliss J, Johnston S, Dowsett M, Rimawi M, On behalf of the PALLET Trialists. The Institute of Cancer Research, London, United Kingdom Baylor College of Medicine, Houston, TX; NSABP Foundation, Pittsburgh, PA; University of Pittsburgh Medical Center Cancer Center, Pittsburgh, PA; Pfizer Inc, La Jolla, CA; Royal Marsden Hospital, Sutton, United Kingdom.
PD15-04 Breast Cancer Index and assessment of the Net Treatment Benefit (NTB) of extended endocrine therapy in HR+ breast cancer
Buyse M, Wong J, Salvaggio S, Chiem J-C, Zhang Y, Treuner K, Meershoek-Klein Kranenbarg E, De Backer M, Liefers G-J, Schnabel CA. International Drug Development Institute, Louvain-la-Neuve, Belgium Biotheranostics, Inc., San Diego, CA; Leiden University Medical Center, Leiden, Netherlands; University of Louvain, Louvain-la-Neuve, Belgium.
PD15-05 Assessment of estrogen receptor (ESR1) mRNA expression for prediction of extended aromatase inhibitor benefit in HR-positive breast cancer using NRG Oncology/NSABP B-42
Mamounas E, Bandos H, Rastogi P, Crager MR, Mies C, Lucas PC, Geyer, Jr CE, Fehrenbacher L, Graham ML, Chia SKL, Brufsky AM, Walshe JM, Soori GS, Dakhil SR, Paik S, Swain SM, Baehner FL, Shak S, Wolmark N. NSABP/NRG Oncology, and Orlando Health Cancer Institute, Orlando, FL; NSABP/NRG Oncology, and The University of Pittsburgh, Pittsburgh, FL; NSABP/NRG Oncology, and UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, and Magee-Womens Hospital, Pittsburgh, PA; Exact Sciences, Precision Oncology, Redwood City, CA; NSABP/NRG Oncology, and UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA; NSABP/NRG Oncology, and Houston Methodist Cancer Center, Houston, TX; NSABP/NRG Oncology, and Kaiser Permanente Oncology Clinical Trials Northern CA,, Novato, CA; NSABP/NRG Oncology, and Waverly Hematology Oncology, Cary, NC; NSABP/NRG Oncology, and British Columbia Cancer Agency, Vancouver, BC, Canada NSABP/NRG Oncology, UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, and Magee-Womens Hospital, Pittsburgh, PA; NSABP/NRG Oncology, and Cancer Trials Ireland, St. Vincent's University Hospital, Dublin, Ireland NSABP/NRG Oncology, and Florida Cancer Specialists, Fort Myers, FL; NSABP/NRG Oncology, and Cancer Center of Kansas, Wichita, LA; NSABP/NRG Oncology, and Yonsei University College of Medicine, Seoul, Korea, Republic of NSABP/NRG Oncology, and Georgetown Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, DC; NSABP/NRG Oncology, and The University of Pittsburgh, Pittsburgh, PA.
PD15-06 Estrogen receptor expression thresholds by IHC and mRNA for Ki67 response to aromatase inhibition: A POETIC study
Lopez Knowles E, Detre S, Hills M, Schuster GF, Cheang MCU, Tovey H, Kilburn L, Bliss J, Robertson J, Smith I, Dowsett M, POETIC investigators. ICR, London, United KingdomRMH, London, United Kingdom Queens Medical Centre, Nottingham, United Kingdom.
PD15-07 Effect of pertuzumab plus neoadjuvant trastuzumab-based chemotherapy in early-stage HER2-positive breast cancer according to BluePrint molecularly defined breast cancer subtypes
Liefaard MC, van der Voort A, Sanders J, Vonk S, Horlings HM, Siesling S, de Munck L, van Leeuwen-Stok E, Kleijn M, Mittempergher L, Kuilman MM, Lips EH, Sonke GS. Netherlands Cancer Institute, Amsterdam, Netherlands Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, Netherlands Dutch Breast Cancer Research Group (BOOG), Amsterdam, Netherlands Agendia, Amsterdam, Netherlands.
PD15-08 Window of opportunity trial of neoadjuvant olaparib and durvalumab for triple negative or low ER-positive breast cancer
Im S-A, Lee K-H, Min A, Lee D, Kim TY, Ryu HS, Koh J, Cheon G-J, Shin Y-J, Kim Y, Moon H-G, Han W, Lee H-B, Diolaiti M, Quigley D, Ashworth A, Cho N. Seoul National University Hospital, Seoul, Korea, Republic of Cancer Research Institute, Seoul National University, Seoul, Korea, Republic of UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA.